Table 4 Detailed analysis of therapy administered during the trial
From: Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
| Â | Chemotherapy | Endocrine therapy | Trastuzumab |
|---|---|---|---|
ER status | |||
 Negative | 63 / 76 (83%) | 3 / 76 (4%) | 20 / 76 (26%) |
 Positive | 135 / 174 (78%) | 50 / 174 (29%) | 35 / 174 (20%) |
PR status | |||
 Negative | 81 / 101 (80%) | 13 / 101 (13%) | 27 / 101 (27%) |
 Positive | 117 / 149 (79%) | 40 / 149 (27%) | 28 / 149 (19%) |
HER2 status | |||
 Negative | 112 / 143 (78%) | 34 / 143 (24%) | 3 / 144 (2%) |
 Positive | 66 / 76 (87%) | 7 / 76 (9%) | 44 / 77 (57%) |
Circulating tumor cells | |||
  ≥ 5 CTCs / 7.5 ml | 100 / 122 (82%) | 25 / 122 (21%) | 19 / 122 (16%) |
  < 5 CTCs / 7.5 ml | 94 / 123 (76%) | 26 / 123 (21%) | 34 / 123 (28%) |
RAS p21 | |||
 Elevated | 25 / 29 (86%) | 2 / 29 (7%) | 9 / 29 (31%) |
 Non elevated | 174 / 222 (78%) | 51 / 222 (23%) | 46 / 222 (21%) |